ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 496 for:    pharmacogenomics

Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03322189
Recruitment Status : Enrolling by invitation
First Posted : October 26, 2017
Last Update Posted : September 14, 2018
Sponsor:
Collaborators:
PAS Research
TRIDENS Clinical Research
Information provided by (Responsible Party):
Data Collection Analysis Business Management

Brief Summary:
Current providers' standard operating procedures on pharmacogenomic testing patients

Condition or disease Intervention/treatment
Pharmacogenomic Genetic: pharmacogenomic

Detailed Description:
The general design of this study is collecting data and reviewing Principal Investigators' Standard Operating Procedures on Pharmacogenomic testing and changes made to their specific SOP.

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Other
Time Perspective: Other
Official Title: Medical Provider Experience and Assessment on Documenting Prescribing and Plan of Care Changes Due to Pharmacogenomics Testing
Actual Study Start Date : March 22, 2017
Estimated Primary Completion Date : March 22, 2020
Estimated Study Completion Date : April 1, 2020

Intervention Details:
  • Genetic: pharmacogenomic
    Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP


Primary Outcome Measures :
  1. Provider Structures and Processes [ Time Frame: 36 months ]
    Plan of Care Changes due to Pharmacogenomic testing. Provider based observational survey system on the health and well-being of patients and populations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Current standard operating procedures for providers
Criteria

Inclusion Criteria:

  • Must be a Medical Practitioner

    • Medical Doctor (MD)
    • Doctor of Osteopathic (DO)
    • Physician Assistant (PA)
    • Advanced Practice Registered Nurse (APRN)
    • Nurse Practioner (NP)
  • Must have a current standard operating procedure that includes obtaining/reviewing medical history.

Exclusion Criteria:

  • Government-funded insurance data cannot be included in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03322189


Locations
United States, Florida
DCABM
Land O' Lakes, Florida, United States, 33558
Sponsors and Collaborators
Data Collection Analysis Business Management
PAS Research
TRIDENS Clinical Research

Responsible Party: Data Collection Analysis Business Management
ClinicalTrials.gov Identifier: NCT03322189     History of Changes
Other Study ID Numbers: PAS1463
First Posted: October 26, 2017    Key Record Dates
Last Update Posted: September 14, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No